Study Complete
Sponsor ID
20180109
Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – DOSE Finding Study
Study Details
Evaluate the effect of olpasiran administered subcutaneously (SC) compared with placebo, on percent change from baseline in lipoprotein(a) (Lp[a]).
Protocol Summary
Primary Outcome Measures
Percent change in Lp(a)
Timeframe: Baseline and week 36
Secondary Outcome Measures
Percentage change from baseline in Lp(a)
Timeframe: Baseline and week 48
Percentage change from baseline in low-density lipoprotein cholesterol (LDL-C)
Timeframe: Baseline and Weeks 36 and 48
Percentage change in Apolipoprotein(B) (ApoB)
Timeframe: Baseline and weeks 36 and 48
Maximum observed concentration (Cmax) of Olpasiran
Timeframe: 48 weeks
Area under the concentration-time curve (AUC) of Olpasiran
Timeframe: 48 weeks
Study Documents
Plain Language Summary of Results
Available Language(s): English, Danish, Dutch, French (Canadian), Icelandic, Japanese
Locations
Location
Westside Medical Associates of Los Angeles
Beverly Hills, CA, United States, 90211
Status
Recruiting
Location
Royal Prince Alfred Hospital
Camperdown, NSW, Australia, 2050
Status
Recruiting
Location
Linear Clinical Research Limited
Nedlands, WA, Australia, 6009
Status
Recruiting
Location
Johns Hopkins
Baltimore, MD, United States, 21287
Status
Recruiting
Location
Monash Medical Centre
Clayton, VIC, Australia, 3168
Status
Recruiting
Location
Baylor College of Medicine
Houston, TX, United States, 77030
Status
Recruiting
Showing {first} - {last} of {total} Results